Rare Cancer News & Clinical Trials » Trial

Prospective Evaluation of the Ablation Therapy With Bipolar Radio Frequency for Nonresectable Bile Duct Cancer

Posted: September 20th, 2018, 2:00pm GMT

Condition: Nonresectable Bile Duct Cancer
Intervention: Device: Ablation Therapy
Sponsor: Institut Paoli-Calmettes
Recruiting

Permalink for 'A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma'

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Posted: September 3rd, 2018, 2:00pm GMT

Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Not yet recruiting

Personal Resilience Empowerment Program Study

Posted: August 23rd, 2018, 2:00pm GMT

Conditions: Lung Cancer; Cholangiocarcinoma; Pancreatic Cancer; Liver Cancer
Intervention: Behavioral: Personal Resilience Empowerment Program including 5 sessions with health coaches
Sponsor: Hackensack Meridian Health
Recruiting

The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer

Posted: August 20th, 2018, 2:00pm GMT

Conditions: Pancreas Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Other: Measurement of triceps skinfold thickness
Sponsor: Samsung Medical Center
Recruiting

Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma

Posted: August 16th, 2018, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Biological: MUC-1 CART cell immunotherapy
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting

Fluorescence Image Guided Surgery in Cholangiocarcinoma

Posted: August 8th, 2018, 2:00pm GMT

Condition: Hilar Cholangiocarcinoma
Interventions: Drug: Bevacizumab-IRDye800CW; Device: near infrared (NIR) fluorescence imaging
Sponsor: University Medical Center Groningen
Not yet recruiting

Trastuzumab in HER2-positive Biliary Tract Cancer

Posted: August 2nd, 2018, 2:00pm GMT

Conditions: Cholangiocarcinoma; Biliary Tract Cancer; HER-2 Protein Overexpression; HER-2 Gene Amplification
Intervention: Drug: Trastuzumab
Sponsor: Changhoon Yoo
Not yet recruiting

Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members

Posted: August 2nd, 2018, 2:00pm GMT

Condition: Gastrointestinal Cancer
Intervention: Other: Surgeon-palliative care team co management
Sponsors: Stanford University; Patient-Centered Outcomes Research Institute
Not yet recruiting

Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

Posted: July 27th, 2018, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: mFOLFOXIRI
Sponsor: Khon Kaen University
Recruiting

$Permalink for 'Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene'$

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Posted: July 26th, 2018, 2:00pm GMT

Conditions: HER2-positive Breast Cancer; HER2 Gene Mutation; HER-2 Gene Amplification; HER2 Positive Gastric Cancer; Salivary Gland Cancer; Salivary Gland Tumor; Salivary Gland Carcinoma; Salivary Gland Neoplasms; Lung Cancer; Colo-rectal Cancer; Rare Diseases; Solid Tumor; Recurrent Gastric Cancer; Recurrent Colon Cancer; Recurrent Breast Cancer; Head and Neck Cancer; Head and Neck Carcinoma; Bladder Cancer; Cervical Cancer; Liver Cancer; Bile Duct Cancer; Urologic Cancer; Pancreatic Cancer; Prostate Cancer; Recurrent Prostate Cancer; Rectal Cancer; Recurrent Ovarian Carcinoma; Recurrent Renal Cell Cancer; Rectal Cancer Stage II; Rectal Cancer Stage I; Rectal Cancer Stage III; Skin Cancer; Mouth Cancer; Lip Cancer Stage I; Tongue Cancer; Breast Neoplasm Malignant Primary; Larynx Cancer; Tonsil Cancer; Palate Cancer; Mucoepidermoid Carcinoma; Primary Peritoneal Carcinoma; Mucinous Adenocarcinoma Gastric; Mucinous Breast Cancer Recurrent; Cholangiocarcinoma
Intervention: Drug: A166
Sponsor: Klus Pharma Inc.
Recruiting

Permalink for 'Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer'

Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer

Posted: June 20th, 2018, 2:00pm GMT

Conditions: Breast Carcinoma; Cholangiocarcinoma; Colorectal Carcinoma; Gastric Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma; Prostate Carcinoma
Interventions: Other: Interview; Other: Survey Administration
Sponsors: University of Southern California; National Cancer Institute (NCI)
Recruiting

Fluorescence QRH-882260 Peptide Imaging in the Bile Duct

Posted: February 19th, 2018, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: QRH-882260 Heptapeptide
Sponsors: D. Kim Turgeon, MD; University of Washington
Not yet recruiting

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

Posted: November 13th, 2017, 3:00pm GMT

Conditions: Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer
Intervention: Drug: Abemaciclib
Sponsors: Jules Bordet Institute; Eli Lilly and Company
Not yet recruiting

A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors

Posted: November 6th, 2017, 3:00pm GMT

Conditions: Melanoma; Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Solid Tumor
Interventions: Drug: CDX-1140; Drug: CDX-301
Sponsor: Celldex Therapeutics
Recruiting

Permalink for 'Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS, and GEM; and CIS and GEM Alone in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenoc'

Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS, and GEM; and CIS and GEM Alone in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenoc

Posted: August 31st, 2017, 2:00pm GMT

Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma, Extrahepatic; Gallbladder Adenocarcinoma
Interventions: Drug: PEGPH20; Drug: CIS; Drug: GEM; Drug: Atezolizumab
Sponsor: Halozyme Therapeutics
Recruiting

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Posted: August 22nd, 2017, 2:00pm GMT

Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Carcinoma
Interventions: Biological: Durvalumab; Drug: Guadecitabine
Sponsors: University of Southern California; National Cancer Institute (NCI); Van Andel Research Institute
Recruiting

Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures

Posted: July 7th, 2017, 2:00pm GMT

Conditions: Cholangiocarcinoma; Stricture; Bile Duct
Interventions: Procedure: Biopsies of bile duct stricture with pediatric biopsy forceps; Procedure: Biopsies of bile duct stricture with cholangioscopy-directed biopsies
Sponsors: Stanford University; University of Rochester; The University of Texas Health Science Center, Houston
Recruiting

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Posted: July 2nd, 2017, 2:00pm GMT

Conditions: Mesothelioma; Uveal Melanoma; Renal Cell Carcinoma; Cholangiocarcinoma
Intervention: Drug: Niraparib
Sponsors: University of Florida; Tesaro, Inc.
Recruiting

Permalink for 'Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer'

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Posted: June 28th, 2017, 2:00pm GMT

Conditions: Gallbladder Carcinoma; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Cholangiocarcinoma
Interventions: Drug: Atezolizumab; Drug: Cobimetinib; Other: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)
Recruiting

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Posted: April 5th, 2017, 2:00pm GMT

Condition: Neoplasms
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Anetumab ravtansine (BAY94-9343)
Sponsors: Bayer; ImmunoGen, Inc.; MorphoSys AG
Recruiting

Permalink for 'A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors'

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Posted: March 7th, 2017, 3:00pm GMT

Condition: Advanced Solid Tumors Cancer
Interventions: Drug: ABBV-368; Drug: ABBV-181
Sponsor: AbbVie
Recruiting

Permalink for 'Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy'

Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy

Posted: October 5th, 2016, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: INCB054828
Sponsor: Incyte Corporation
Recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Posted: July 15th, 2016, 2:00pm GMT

Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary Origin; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Placental-Site Gestational Trophoblastic Tumor; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Malignant Transformation; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting

Permalink for 'SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma'

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

Posted: June 21st, 2016, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Sponsor: Sirtex Medical
Recruiting

OLAParib COmbinations

Posted: October 15th, 2015, 2:00pm GMT

Condition: Cancer
Interventions: Drug: AZD2281; Drug: AZD5363; Drug: AZD1775; Drug: AZD6738
Sponsors: Joseph Paul Eder; Dana-Farber Cancer Institute; Vanderbilt-Ingram Cancer Center; The Cleveland Clinic
Recruiting

Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

Posted: October 15th, 2015, 2:00pm GMT

Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Carcinoma, Ductal, Breast; Melanoma; Solid Tumors; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas
Intervention: Drug: Larotrectinib LOXO-101
Sponsors: Loxo Oncology, Inc.; Bayer
Recruiting

Permalink for 'Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)'

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Posted: October 5th, 2015, 2:00pm GMT

Conditions: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
Intervention: Drug: Entrectinib
Sponsor: Hoffmann-La Roche
Recruiting

90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

Posted: July 31st, 2015, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Medical University of South Carolina
Recruiting

$Permalink for 'Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)'$

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Posted: June 8th, 2015, 2:00pm GMT

Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Binimetinib; Drug: Capivasertib; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dasatinib; Drug: Defactinib; Drug: FGFR Inhibitor AZD4547; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Posted: May 30th, 2014, 2:00pm GMT

Condition: Advanced Cholangiocarcinoma
Intervention: Drug: BGJ398
Sponsor: Novartis Pharmaceuticals
Recruiting

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Posted: May 1st, 2014, 2:00pm GMT

Condition: Cholangiocarcinoma
Interventions: Drug: CX-4945; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Senhwa Biosciences, Inc.
Recruiting

Rare Cancer News & Clinical Trials » Trial - Cholangiocarcinoma

Feeds

Trial - Cholangiocarcinoma (31 unread)

Posted: September 20th, 2018, 2:00pm GMT

Posted: September 3rd, 2018, 2:00pm GMT

Posted: August 23rd, 2018, 2:00pm GMT

Posted: August 20th, 2018, 2:00pm GMT

Posted: August 16th, 2018, 2:00pm GMT

Posted: August 8th, 2018, 2:00pm GMT

Posted: August 2nd, 2018, 2:00pm GMT

Posted: August 2nd, 2018, 2:00pm GMT

Posted: July 27th, 2018, 2:00pm GMT

Posted: July 26th, 2018, 2:00pm GMT

Posted: June 20th, 2018, 2:00pm GMT

Posted: February 19th, 2018, 3:00pm GMT

Posted: November 13th, 2017, 3:00pm GMT

Posted: November 6th, 2017, 3:00pm GMT

Posted: August 31st, 2017, 2:00pm GMT

Posted: August 22nd, 2017, 2:00pm GMT

Posted: July 7th, 2017, 2:00pm GMT

Posted: July 2nd, 2017, 2:00pm GMT

Posted: June 28th, 2017, 2:00pm GMT

Posted: April 5th, 2017, 2:00pm GMT

Posted: March 7th, 2017, 3:00pm GMT

Posted: October 5th, 2016, 2:00pm GMT

Posted: July 15th, 2016, 2:00pm GMT

Posted: June 21st, 2016, 2:00pm GMT

Posted: October 15th, 2015, 2:00pm GMT

Posted: October 15th, 2015, 2:00pm GMT

Posted: October 5th, 2015, 2:00pm GMT

Posted: July 31st, 2015, 2:00pm GMT

Posted: June 8th, 2015, 2:00pm GMT

Posted: May 30th, 2014, 2:00pm GMT

Posted: May 1st, 2014, 2:00pm GMT